(2009) KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, November 20, 2013

(2009) KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay



Full text 

Conclusion

In summary, KRAS mutation is a common event in ovarian cancer and is more frequently present in carcinoma of lower grade, lower FIGO stage, and in lesions of mucinous histotype. Our results support earlier findings from other groups in a very large number of samples. KRAS mutation was not found to be of prognostic value for patients under standard therapy, but these mutations could emerge as an important factor for individually tailored anti-EGFR therapies.
 

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.